RxDoctor Payments DataLook up a doctor →

Liza Whitacre

Family · Temperance, MINPI 1922592369

Payments from drug & device makers

$9,649in general payments, 2019–2025

Across 582 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$934
  • AstraZeneca$887
  • Amgen$513
  • Pfizer$442
  • plus $4K from 31 others

What the payments were for

  • Food & beverage$9,54999%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,649 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$25,433
Medicare patients
129
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$99,135
OzempicSemaglutide40$72,506
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$67,995
EliquisApixaban46$54,277
FarxigaDapagliflozin Propanediol42$43,309
TrulicityDulaglutide22$37,729
MounjaroTirzepatide19$27,781
WegovySemaglutide15$25,197
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,244
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$14,124
Spiriva RespimatTiotropium Bromide15$11,878
Breo ElliptaFluticasone/Vilanterol19$9,914
VeozahFezolinetant12$6,363
Icosapent Ethyl14$6,352
VascepaIcosapent Ethyl15$5,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$355$111,01390 claims
Novo NordiskOzempic, Wegovy$1,593$97,70255 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$360$92,03396 claims
Lilly USA, LLCTrulicity, Mounjaro$934$65,51041 claims
AstraZenecaFarxiga, Breztri Aerosphere$887$57,55363 claims
PfizerEliquis, Paxlovid$442$57,10259 claims
Astellas Pharma US IncVeozah$14$6,36312 claims
AbbVieSynthroid$1,696$90120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Temperance

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →